Cogent Biosciences, Inc. (COGT) is a publicly traded company in the Healthcare sector, operating within the Biotechnology industry. The company is headquartered in Waltham, MA, United States. The current CEO is Andrew R. Robbins.
COGT has IPO date of 2018-03-29, 205 full-time employees, listed on the NASDAQ Global Select, a market capitalization of $5.92B.
Cogent Biosciences, Inc. is a biotechnology company focused on developing precision therapies for genetically defined diseases. The company's lead product candidate, CGT9486, is a selective tyrosine kinase inhibitor designed to treat systemic mastocytosis and advanced gastrointestinal stromal tumors by targeting specific KIT mutations. Cogent also holds a licensing agreement with Plexxikon Inc. for the development and commercialization of bezuclastinib. Headquartered in Cambridge, Massachusetts, the company was founded in 2014 and rebranded from Unum Therapeutics Inc. to Cogent Biosciences, Inc. in October 2020.
